NO161915B - PROCEDURE FOR N-DEMETHYLING OF MORPHINAN ALKALOIDS. - Google Patents
PROCEDURE FOR N-DEMETHYLING OF MORPHINAN ALKALOIDS. Download PDFInfo
- Publication number
- NO161915B NO161915B NO852838A NO852838A NO161915B NO 161915 B NO161915 B NO 161915B NO 852838 A NO852838 A NO 852838A NO 852838 A NO852838 A NO 852838A NO 161915 B NO161915 B NO 161915B
- Authority
- NO
- Norway
- Prior art keywords
- group
- hydrogen atom
- general formula
- carbon atoms
- phosgene
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 14
- 229930013053 morphinan alkaloid Natural products 0.000 title claims description 6
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 title description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims abstract description 21
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 230000008569 process Effects 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 3
- 239000002904 solvent Substances 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 12
- 239000003513 alkali Substances 0.000 claims description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical group C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 238000009413 insulation Methods 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 30
- -1 alkali metal hydrogen carbonates Chemical class 0.000 abstract description 10
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 abstract description 9
- 230000007062 hydrolysis Effects 0.000 abstract description 7
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 5
- 238000002955 isolation Methods 0.000 abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 125000004423 acyloxy group Chemical group 0.000 abstract 5
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 abstract 5
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 abstract 1
- 150000008041 alkali metal carbonates Chemical class 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 150000003810 morphinanes Chemical class 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000010520 demethylation reaction Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- 238000001816 cooling Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 5
- 229960000240 hydrocodone Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 150000003512 tertiary amines Chemical class 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229910017053 inorganic salt Inorganic materials 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 150000003673 urethanes Chemical class 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 3
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 2
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- QVIUKMVKLLVCDU-ATNYCFDYSA-N acetylmorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O QVIUKMVKLLVCDU-ATNYCFDYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 150000001912 cyanamides Chemical class 0.000 description 2
- 239000012649 demethylating agent Substances 0.000 description 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 2
- 229960000920 dihydrocodeine Drugs 0.000 description 2
- 229960004578 ethylmorphine Drugs 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JGORUXKMRLIJSV-YNHQPCIGSA-N (4r,4ar,7ar,12bs)-9-methoxy-2,3,4,4a,5,6,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O=C([C@@H]1O2)CC[C@H]3[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4 JGORUXKMRLIJSV-YNHQPCIGSA-N 0.000 description 1
- HVQUMOKQAJNIKK-ZTYRTETDSA-N (4r,4ar,7s,7ar,12bs)-1,2,3,4,4a,5,6,7,7a,13-decahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound C([C@@H](NCC1)[C@@H]2CC[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 HVQUMOKQAJNIKK-ZTYRTETDSA-N 0.000 description 1
- IKGNKASQBMZRJL-KOFBORESSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-1,2,3,4,4a,5,6,7,7a,13-decahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol Chemical compound O[C@H]([C@@H]1O2)CC[C@H]3[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4 IKGNKASQBMZRJL-KOFBORESSA-N 0.000 description 1
- YYCRAERBSFHMPL-XFKAJCMBSA-N (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,7a,13-tetrahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O=C([C@@H]1O2)C=C[C@@]3(O)[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 YYCRAERBSFHMPL-XFKAJCMBSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- YYCRAERBSFHMPL-UHFFFAOYSA-N 14beta-Hydroxycodeinone Natural products O1C2C(=O)C=CC3(O)C4CC5=CC=C(OC)C1=C5C23CCN4C YYCRAERBSFHMPL-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- MFXFQKMUCYHPFQ-BKRJIHRRSA-N 6-monoacetylcodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](OC(C)=O)[C@@H]1OC1=C2C3=CC=C1OC MFXFQKMUCYHPFQ-BKRJIHRRSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VXXGFLDAQXZKQE-QLBVAGGCSA-N C(C)OC(=O)N1[C@H]2[C@@H]3CCC([C@H]4[C@@]3(C=3C(=C(C=CC3C2)OC)O4)CC1)=O Chemical compound C(C)OC(=O)N1[C@H]2[C@@H]3CCC([C@H]4[C@@]3(C=3C(=C(C=CC3C2)OC)O4)CC1)=O VXXGFLDAQXZKQE-QLBVAGGCSA-N 0.000 description 1
- PZDCDDVCYJEWCS-YYNKCLGXSA-N ClC(=O)N1[C@H]2[C@@H]3CCC([C@H]4[C@@]3(C=3C(=C(C=CC3C2)OC)O4)CC1)=O Chemical compound ClC(=O)N1[C@H]2[C@@H]3CCC([C@H]4[C@@]3(C=3C(=C(C=CC3C2)OC)O4)CC1)=O PZDCDDVCYJEWCS-YYNKCLGXSA-N 0.000 description 1
- CNEQUQYUPUHQTD-VUICDJBSSA-N ClO.C1=CC(O)=C2C=3[C@@]45[C@@H](O2)C(=O)CC[C@H]4[C@@H](CC13)NCC5 Chemical compound ClO.C1=CC(O)=C2C=3[C@@]45[C@@H](O2)C(=O)CC[C@H]4[C@@H](CC13)NCC5 CNEQUQYUPUHQTD-VUICDJBSSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- CWGJBBRZFIPXNZ-UHFFFAOYSA-N [C-]#N.Br Chemical compound [C-]#N.Br CWGJBBRZFIPXNZ-UHFFFAOYSA-N 0.000 description 1
- 229960002948 acetyldihydrocodeine Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- KZOKOEQTKWBKOK-XHQKLZHNSA-N azidomorphine Chemical compound O([C@H]1[C@@H](CC[C@H]23)N=[N+]=[N-])C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O KZOKOEQTKWBKOK-XHQKLZHNSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- WGXZDYPGLJYBJW-UHFFFAOYSA-N chloroform;propan-2-ol Chemical compound CC(C)O.ClC(Cl)Cl WGXZDYPGLJYBJW-UHFFFAOYSA-N 0.000 description 1
- XYYVYLMBEZUESM-CMKMFDCUSA-N codeinone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=CC(=O)[C@@H]1OC1=C2C3=CC=C1OC XYYVYLMBEZUESM-CMKMFDCUSA-N 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- NCXVKLDKUADJPV-PVHGPHFFSA-N diacetyldihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O NCXVKLDKUADJPV-PVHGPHFFSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HNPDNOZNULJJDL-UHFFFAOYSA-N ethyl n-ethenylcarbamate Chemical class CCOC(=O)NC=C HNPDNOZNULJJDL-UHFFFAOYSA-N 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- HKOIXWVRNLGFOR-KOFBORESSA-N norcodeine Chemical compound O[C@H]([C@@H]1O2)C=C[C@H]3[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4 HKOIXWVRNLGFOR-KOFBORESSA-N 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical group C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 1
- 229930004668 tropane alkaloid Natural products 0.000 description 1
- 150000003813 tropane derivatives Chemical class 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005945 von Braun degradation reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Abstract
Description
Foreliggende oppfinnelse angår en ny fremgangsmåte for fremstilling av forbindelser med N-demethylmorfinanskjelett av generell formel (III) The present invention relates to a new process for the preparation of compounds with an N-demethylmorphine skeleton of general formula (III)
hvori in which
Z betegner CH2~CH2 eller CH=CH, Z denotes CH2~CH2 or CH=CH,
Y er et oxygenatom eller R og R4 hvori R3 betegner et Y is an oxygen atom or R and R4 in which R3 denotes a
hydrogenatom, og R^ betegner hydrogen, hydrogen atom, and R^ denotes hydrogen,
R^ er et hydrogenatom eller en C-^^-alkylgruppe. R 1 is a hydrogen atom or a C 1-3 alkyl group.
Erstatning av N-methylgruppen i morfinanalkaloider med en annen alkylgruppe førte til oppdagelsen av morfinanta-gonister som er betydningsfulle ut fra et farmakologisk og terapeutisk synspunkt, såvel som separering av den agonist-iske og antagonistiske effekt (Adv. in Biochem. Psychopharm. bind 8: Narcotlc Antagonists (Raven Press, New York 1974); Replacement of the N-methyl group in morphine alkaloids with another alkyl group led to the discovery of morphine antagonists which are significant from a pharmacological and therapeutic point of view, as well as separation of the agonistic and antagonistic effects (Adv. in Biochem. Psychopharm. volume 8 : Narcotlc Antagonists (Raven Press, New York 1974);
E. F. Hahn: Drugs of the Future 9( 6), 443 (1984)). E. F. Hahn: Drugs of the Future 9( 6), 443 (1984)).
Da morfinanalkaloidene (morfin, codein, tebain) kan erholdes fra naturlige plantekilder, har de fleste fremgangsmåter gått ut på å forsøke å fremstille sekundære aminer fra de ovenfor angitte N-methyl-t-aminer. (Det sekundære amin kan omdannes til den ønskede forbindelse senere ved N-alkyler-ing). Det er hensiktsmessig å erstatte N-methylgruppen med en lett hydrolyserbar funksjonell gruppe. As the morphinan alkaloids (morphine, codeine, thebaine) can be obtained from natural plant sources, most methods have involved trying to produce secondary amines from the above-mentioned N-methyl-t-amines. (The secondary amine can be converted to the desired compound later by N-alkylation). It is appropriate to replace the N-methyl group with an easily hydrolyzable functional group.
De krav som stilles til N-demethyleringsmidlet, er som følger: det skal være billig, stabilt, lett å fremstille, det skal utvise en tilstrekkelig reaktivitet og sikre gode utbytter og skal ikke være toksisk. The requirements for the N-demethylating agent are as follows: it must be cheap, stable, easy to manufacture, it must exhibit sufficient reactivity and ensure good yields and must not be toxic.
Bromcyan som tidligere ble vidt anvendt for N-demethylering av morfinanskjelettet (H.A. Hageman: Org. Reactions 1_, 198 (1953)), er gradvis blitt fortrengt av klormaursyre-estere i løpet av de siste få år. Den største ulempe ved bromcyanet er at det er relativt toksisk, på grunn av dets flyktige karakter er det hensiktsmessig å fremstille dette friskt før bruk, og på den annen side har flere forfattere beskrevet dets eksplosive karakter. Cyan bromide, which was formerly widely used for N-demethylation of the morphinan skeleton (H.A. Hageman: Org. Reactions 1_, 198 (1953)), has been gradually displaced by chloroformate esters during the last few years. The biggest disadvantage of cyanogen bromide is that it is relatively toxic, due to its volatile nature it is appropriate to prepare this fresh before use, and on the other hand, several authors have described its explosive nature.
Den sure (eller alkaliske) hydrolyse av cyanamidene dannet ved reaksjonen i henhold til von Braun, kan føre til en delvis spaltning (eller omdannelse) av molekylet i visse tilfeller (A. C. Currie, G. T. Newbold, F. S. Spring: J. Chem. Soc. 4693 (1961)), eller reaksjonen stopper i urea-fasen (K. W. Bentley, D. G. Hardy: J. Am. Chem. Soc. 89, 3281 (1967)). The acid (or alkaline) hydrolysis of the cyanamides formed by the von Braun reaction may lead to a partial cleavage (or conversion) of the molecule in certain cases (A. C. Currie, G. T. Newbold, F. S. Spring: J. Chem. Soc. 4693 (1961)), or the reaction stops in the urea phase (K.W. Bentley, D.G. Hardy: J. Am. Chem. Soc. 89, 3281 (1967)).
I motsetning til dette kan klormaursyreestrene lett behandles, de er mindre toksiske forbindelser, og rensing av disse kan lett utføres ved destillasjon. Methyl-, ethyl- In contrast, the chloroformic acid esters can be easily processed, they are less toxic compounds, and purification of these can easily be carried out by distillation. methyl, ethyl
og fenylestrene som først ble anvendt, ga glimrende utbytter (8 5-95%) ved forløpet av N-demethyleringen and the phenylesters that were first used gave excellent yields (85-95%) in the course of the N-demethylation
(M.M. Abdel-Monem, P.S. Portoghese: J. Med. Chem. !L5, 208 (M.M. Abdel-Monem, P.S. Portoghese: J. Med. Chem. !L5, 208
(1972); G.A. Brine, K.G. Boldt, C.K. Hart, F.I. Carroll: Organic Prep. Proced. Int. 8, 103 (1976); K.C. Rice, (1972); GO. Brine, K.G. Boldt, C.K. Hart, F.I. Carroll: Organic Prep. Procedure Int. 8, 103 (1976); K.C. Rice,
E.L. May: J. Heterocyclic Chem. 14, 665 (1977)). E.L. May: J. Heterocyclic Chem. 14, 665 (1977)).
Det ble funnet at isolering av urethan-mellomproduktene er nødvendig, og disse kan direkte omdannes av en base eller et hydrazin. Da den ovenfor angitte hydrolyse er relativt langvarig (24 til 48 timer) og da det i løpet av dette tidsrom kan finne sted spaltning og bireaksjoner, er i den siste tiden klormaursyre-2,2,2-triklorethylester It was found that isolation of the urethane intermediates is necessary and these can be directly converted by a base or a hydrazine. Since the above-mentioned hydrolysis is relatively long-lasting (24 to 48 hours) and since during this time cleavage and side reactions can take place, in recent times chloroformic acid-2,2,2-trichloroethyl ester
(I.J. Borowitz, V. Diakiw: J. Heterocyclic Chem. 12, 1123 (I.J. Borowitz, V. Diakiw: J. Heterocyclic Chem. 12, 1123
(1975); J.I. DeGraw, J.H. Lawson, J.L. Crase, H.L. Johnson, M. Ellis, E.T. Uyeno, G.H. Loew, D.S. Berkowitz: J. Med. Chem. _21, 415 (1978)) og klormaursyre-vinylesteren blitt (1975); J.I. DeGraw, J.H. Lawson, J.L. Crase, H.L. Johnson, M. Ellis, E.T. Uyeno, G.H. Loew, D.S. Berkowitz: J. Med. Chem. _21, 415 (1978)) and the chloroformic acid vinyl ester became
foreslått for N-demethylerIngen. proposed for N-demethylerNone.
Fordelen med triklorethylesteren er at den er reaktiv og at de dannede urethaner lett kan spaltes med aktivert sinkpulver. Det er imidlertid en ulempe at spaltningen av urethanene erholdt fra 14-acyloxymorfinanene, er ledsaget av 0—>N-acyl-vandring (tysk offentliggjørelsesskrift nr. 2 727 805) som ikke muliggjør en direkte fremstilling av N-demethylderivatet. The advantage of the trichloroethyl ester is that it is reactive and that the formed urethanes can be easily split with activated zinc powder. However, it is a disadvantage that the cleavage of the urethanes obtained from the 14-acyloxymorphinans is accompanied by 0—>N-acyl migration (German publication no. 2 727 805) which does not enable a direct preparation of the N-demethyl derivative.
I litteraturen finnes også eksempler hvori et sink-kompleks av N-demethylderivatet dannes (N.P. Peet: J. Pharm. Sei. 69, 1447 (1980)). Ifølge litteraturangivelsene er klormaursyre-vinylesteren det beste N-demethyleringsmiddel (US patentskrift 3 905 981, 4 141 897, 4 161 597). Dette middel er meget reaktivt på grunn av den elektron-tiltrekk-ende karakter av vinylgruppen slik at det sikrer kvantitativ omsetning. In the literature there are also examples in which a zinc complex of the N-demethyl derivative is formed (N.P. Peet: J. Pharm. Sei. 69, 1447 (1980)). According to the literature, the chloroformic acid vinyl ester is the best N-demethylating agent (US Patent 3,905,981, 4,141,897, 4,161,597). This agent is highly reactive due to the electron-withdrawing character of the vinyl group so that it ensures quantitative turnover.
Hvis vinylurethanene behandles med en ekvivalent mengde syre (saltsyre, hydrogenbromid), finner addisjon sted, og når de kokes med methanol, dannes et salt av det sekundære amin. Spaltning av urethanet finner således sted under meget milde reaksjonsbetingelser slik at det sekundære amin kan erholdes i et godt utbytte og i høy renhet. If the vinyl urethanes are treated with an equivalent amount of acid (hydrochloric acid, hydrogen bromide), addition takes place, and when boiled with methanol, a salt of the secondary amine is formed. Cleavage of the urethane thus takes place under very mild reaction conditions so that the secondary amine can be obtained in good yield and in high purity.
Hvis urethanene dannet fra 14-0-acylmorfinaner behandles med en syre, dannes saltet (hydroklorid, hydrobromid etc.) av 14-'0-acyl-N-demethylforbindelsen, dvs. at det i dette tilfelle ikke finner sted noen 0—^N-acyl-vandring. I tillegg til de ovenfor angitte fordeler skal det imidlertid bemerkes at fremstilling av klormaursyre-vinylesteren er problematisk (på grunn av pyrolyse), hvilket gjør det nød-vendig å studere ytterligere N-demethyleringsmetoder. Difosgenet ble valgt fordi dette med hell er blitt anvendt for N-demethylering av tropanalkaloidene. Disfosgenet eller klormaursyre-triklormethylesteren kan lett fremstilles ved klorering av klormaursyre-methylester (A. Efrati, I. Feinstein, L. Wackerle, A. Goldman: J. Org. Chem. 45, 4059 (1980)? K. Kurita, Y. Iwakura: Org. Synth. J59, 195, If the urethanes formed from 14-0-acylmorphinans are treated with an acid, the salt (hydrochloride, hydrobromide, etc.) of the 14-'0-acyl-N-demethyl compound is formed, i.e. that in this case no 0-^N takes place -acyl migration. In addition to the advantages stated above, however, it should be noted that the production of the chloroformic acid vinyl ester is problematic (due to pyrolysis), which makes it necessary to study further N-demethylation methods. Diphosgene was chosen because this has been successfully used for N-demethylation of the tropane alkaloids. The disphosgene or chloroformate trichloromethyl ester can be readily prepared by chlorination of chloroformate methyl ester (A. Efrati, I. Feinstein, L. Wackerle, A. Goldman: J. Org. Chem. 45, 4059 (1980)? K. Kurita, Y. Iwakura: Org. Synth. J59, 195,
(1980)). (1980)).
Da difosgenet oppfører seg i de fleste reaksjoner lik fosgenet (1 mol av difosgen avgir 2 mol fosgen), dets koke-punkt er 128°C, dets spenning er lav (10 mmHg) ved romtemperatur, er i den siste tiden det meget toksiske fosgen mer og mer blitt erstattet med disfosgen. Disfosgenet og fosgen reagerer med tertiære aminer på lignende måte som klormaursyreestrene, methylgruppen avspaltes i form av methylklorid, og carbamoylklorid dannes, og når det gjelder disfosgen, dannes også fosgen (H. Babad, A.D. Zeiler: Chem. Rev. 73f 75 (1973)) . As diphosgene behaves in most reactions similar to phosgene (1 mol of diphosgene gives off 2 mol of phosgene), its boiling point is 128°C, its voltage is low (10 mmHg) at room temperature, recently the highly toxic phosgene more and more being replaced with dysphosgene. The disphosgene and phosgene react with tertiary amines in a similar manner to the chloroformate esters, the methyl group is split off in the form of methyl chloride, and carbamoyl chloride is formed, and in the case of disphosgene, phosgene is also formed (H. Babad, A.D. Zeiler: Chem. Rev. 73f 75 (1973) ).
Fosgen ble foreslått for N-demethylering av tertiære aminer som analogt med reaksjonen ifølge Braun allerede i 1947 (V.A. Rudenko, A.Y. Jakubovich, T.Y. Nikoforova: J. Gen. Chem. (USSR) 17, 2256 (1947); CA. 4_2, 4918e) . Phosgene was proposed for the N-demethylation of tertiary amines as analogous to the reaction according to Braun as early as 1947 (V.A. Rudenko, A.Y. Jakubovich, T.Y. Nikoforova: J. Gen. Chem. (USSR) 17, 2256 (1947); CA. 4_2, 4918e ).
Da fosgen sammen med tertiære aminer kan danne kom-plekser i et amin-fosgenforhold på 1:1 og 1:2 og da det ved spaltning av det sistnevnte dannes et tertiært amin Since phosgene together with tertiary amines can form complexes in an amine-phosgene ratio of 1:1 and 1:2 and since by splitting the latter a tertiary amine is formed
(H. Babad, A.D. Zeiler: Chem. Rev. 73, 75 (1973)), er anvendelse av et fosgenoverskudd egnet fordi også tetrasubsti-tuert urea dannes hvis aminet anvendes i overskudd. (H. Babad, A.D. Zeiler: Chem. Rev. 73, 75 (1973)), the use of an excess of phosgene is suitable because tetrasubstituted urea is also formed if the amine is used in excess.
Banholzer et al. (i britisk patentskrift 1 166 798 og Banholzer et al. (in British patent specification 1 166 798 and
1 167 688 og R. Banholzer, A. Heusner, W. Schulz: Liebigs Ann. Chem. 2227 (1975)) har som de første beskrevet N-demethylering av alkalolder med et tropanskjelett med fosgen og difosgen. Under oppvarming av det erholdte carbamoyl-klor id (isolering er ikke nødvendig) med vann hydrolyserer dette til sekundært aminklorhydrat og carbondioxyd. 1,167,688 and R. Banholzer, A. Heusner, W. Schulz: Liebig's Ann. Chem. 2227 (1975)) were the first to describe N-demethylation of alkaloids with a tropane skeleton with phosgene and diphosgene. During heating of the obtained carbamoyl chloride (isolation is not necessary) with water, this hydrolyzes to secondary amine chloride hydrate and carbon dioxide.
På basis av de ovenfor angitte angivelser syntes det å være hensiktsmessig å undersøke N-demethyleringen av forbindelser med et morfinanskjelett med difosgen da hydrolysen av carbamoylkloridene sannsynligvis ville finne sted under meget mildere betingelser enn av urethanene eller cyanamidene. On the basis of the above indications it seemed appropriate to investigate the N-demethylation of compounds with a morphinane skeleton with diphosgene as the hydrolysis of the carbamoyl chlorides would probably take place under much milder conditions than of the urethanes or cyanamides.
Som en modellforbindelse ble dihydrocodeinon valgt, og det ble konstatert at det avgir det forventede N-klorcarbonyl-N-demethyl-dihydrocodeinon med difosgen i en løs-ning inneholdende 1,2-diklorethan (eller diklormethan, As a model compound, dihydrocodeinone was chosen, and it was found that it emits the expected N-chlorocarbonyl-N-demethyl-dihydrocodeinone with diphosgene in a solution containing 1,2-dichloroethane (or dichloromethane,
kloroform, carbontetraklorid, benzen, toluen). chloroform, carbon tetrachloride, benzene, toluene).
Strukturen av den sistnevnte ble også bekreftet av det faktum at dihydrocodeinonet utviste en lignende reaksjon med fosgen, og på den annen side ble det ved kokning av klor-carbonylforbindelsen med ethanol dannet det urethan som er beskrevet i litteraturen, N-ethoxycarbonyl-N-demethyl-dihydrocodeinon, (G. Horvåth, P. Kerekes, Gy. GaSl, The structure of the latter was also confirmed by the fact that the dihydrocodeinone exhibited a similar reaction with phosgene, and on the other hand, boiling the chloro-carbonyl compound with ethanol produced the urethane described in the literature, N-ethoxycarbonyl-N-demethyl -dihydrocodeinone, (G. Horvåth, P. Kerekes, Gy. GaSl,
R. Bognår: Acta Chim. Acad. Sei. Hung. 8_2, 217 (1974)). R. Book year: Acta Chim. Acad. Pollock. Hung. 8_2, 217 (1974)).
Vannfritt natriumcarbonat katalyserer dannelsen av N-klorcarbonylderivatet i tillegg til at det også er hensiktsmessig å anvende vannfritt natriumcarbonat for binding av mulige syrespor. Deretter oppvarmes N-klorcarbonylderivatet med vann og kan hydrolyseres til N-demethyldihydro-, codeinon-klorhydrat. Anhydrous sodium carbonate catalyzes the formation of the N-chlorocarbonyl derivative, in addition to the fact that it is also appropriate to use anhydrous sodium carbonate to bind possible traces of acid. The N-chlorocarbonyl derivative is then heated with water and can be hydrolysed to N-demethyldihydro, codeinone chlorohydrate.
Hydroxygrupper som stammer fra alkoholer eller fenoler, kan acyleres av disfosgen og fosgen under forløpet for dannelsen av saltsyre, og saltsyre binder det tertiære amin, hvorfor det er hensiktsmessig å beskytte morfinderi-vatene inneholdende en hydroxylgruppe ved acylering. Hydroxy groups originating from alcohols or phenols can be acylated by dysphosgene and phosgene during the formation of hydrochloric acid, and hydrochloric acid binds the tertiary amine, which is why it is appropriate to protect the morphine derivatives containing a hydroxyl group by acylation.
Under forløpet for hydrolysen av carbamoylkloridet dannet ved N-demethylering av 3-0-acetyl-dihydromorfinon, fant det også sted en deacetylering, og N-demethyl-dihydromorfinon-klorhydrat ble dannet. Ved den vandige hydrolyse av 6-0-acetyl-N-klorcarbonyl-N-demethylcodein erholdt fra 6-0-acetylcodein, ble imidlertid 6-0-acetyl-N-demethylcodein dannet, hvorfor hydrolysen når det gjelder morfin, codein, ethylmorfin, dihydrocodein, dihydroethylmorfin, dihydromorfin, ble utført med saltsyre i en konsentrasjon på 5%. Den egnede N-demethylforbindelse ble således isolert som et ensartet produkt. During the course of the hydrolysis of the carbamoyl chloride formed by N-demethylation of 3-O-acetyl-dihydromorphinone, a deacetylation also took place, and N-demethyl-dihydromorphinone chlorohydrate was formed. However, in the aqueous hydrolysis of 6-0-acetyl-N-chlorocarbonyl-N-demethylcodeine obtained from 6-0-acetylcodeine, 6-0-acetyl-N-demethylcodeine was formed, therefore the hydrolysis in the case of morphine, codeine, ethylmorphine, dihydrocodeine, dihydroethylmorphine, dihydromorphine, was performed with hydrochloric acid at a concentration of 5%. The appropriate N-demethyl compound was thus isolated as a uniform product.
Foreliggende fremgangsmåte er egnet for N-demethylering av dihydrocodeinon, dihydromorfinon, codein, dihydrocodein, morfin, dihydromorfin, ethylmorfin, dihydroethylmorfin, desoxycodein-E, dihydrodesoxycodein-E, 14-hydroxy-dihydrocodeinon, 14-hydroxycodeinon, 14-hydroxy-dihydromorfinon, 3-0-benzylmorfin, azidomorfin. The present method is suitable for N-demethylation of dihydrocodeinone, dihydromorphinone, codeine, dihydrocodeine, morphine, dihydromorphine, ethylmorphine, dihydroethylmorphine, desoxycodein-E, dihydrodesoxycodein-E, 14-hydroxy-dihydrocodeinone, 14-hydroxycodeinone, 14-hydroxy-dihydromorphinone, 3 -0-benzylmorphine, azidomorphine.
Fremgangsmåten ifølge oppfinnelsen er kjennetegnet ved at morfinanalkaloider av generell formel (I) The method according to the invention is characterized by the fact that morphine alkaloids of general formula (I)
i in
hvor er R^ eller en acetylgruppe, og Y er Y eller en acetylgruppe, omsettes med fosgen eller difosgen i et løs-ningsmiddel ved temperaturer på fra 0 til 120°C i nærvær av alkalicarbonater/alkalihydrocarbonater, hvoretter det dannede N-klorcarbonyl-N-demethylderivat av generell formel (II) where R is or an acetyl group, and Y is Y or an acetyl group, is reacted with phosgene or diphosgene in a solvent at temperatures of from 0 to 120°C in the presence of alkali carbonates/alkali hydrocarbonates, after which the formed N-chlorocarbonyl-N -demethyl derivative of general formula (II)
hvori Z, Y<1> og R^ er som ovenfor definert, uten isolering oppvarmes med vann eller en fortynnet, uorganisk syre. in which Z, Y<1> and R^ are as defined above, without insulation is heated with water or a dilute, inorganic acid.
Et av de viktige trekk ved oppfinnelsen er den erkjenn-else av det egnede N-klorcarbonyl-N-demethylderivat kan hydrolyseres under milde og enkle reaksjonsbetingelser, dvs. at det ikke skjer noen spaltninger og skadelige bivirkninger, og under fremstillingsforløpet dannes det ingen toksiske modervæsker og avfallsvæsker. One of the important features of the invention is the recognition that the suitable N-chlorocarbonyl-N-demethyl derivative can be hydrolysed under mild and simple reaction conditions, i.e. that no cleavages and harmful side effects occur, and no toxic mother liquors are formed during the manufacturing process and waste fluids.
Anvendelse av fosgen og difosgen er mest fordelaktig i forhold til bromcyanid og klormaursyreestrene når det gjelder reagensenes farlighetsgrad, vansker forbundet med deres fremstilling, pris og deres tilgjengelighet for fremgangsmåter i industriell målestokk. The use of phosgene and diphosgene is most advantageous compared to cyanide bromide and the chloroformate esters in terms of the reagents' degree of danger, difficulties associated with their manufacture, price and their availability for processes on an industrial scale.
Ved fremgangsmåten ifølge oppfinnelsen er anvendelse av difosgen betraktet som mer fordelaktig i forhold til det toksiske fosgen når man tar i betraktning at fosgenet som dannes under forløpet for reaksjonen av fosgen, sikkert kan fjernes fra systemet ved vasking med nitrogen i en egnet vasker. In the method according to the invention, the use of diphosgene is considered more advantageous in relation to the toxic phosgene when one takes into account that the phosgene formed during the course of the reaction of phosgene can be safely removed from the system by washing with nitrogen in a suitable washer.
Fremgangsmåten ifølge oppfinnelsen er egnet for økonomisk fremstilling av N-demethylmorfinanderivatene som er betydningsfulle ut fra et farmakologisk og terapeutisk synspunkt. The method according to the invention is suitable for the economic production of the N-demethylmorphinan derivatives which are important from a pharmacological and therapeutic point of view.
Oppfinnelsen illustreres ytterligere i de etterfølg-ende eksempler. Smeltepunktene ble bestemt på en Koffler-apparatur, og dataene er ikke korrigert. For tynnskikts-kromatografiske undersøkelser ble Merck 5554 silicagel 60F254-folier anvendt. Elueringsmidler: benzenrmethanol = The invention is further illustrated in the following examples. Melting points were determined on a Koffler apparatus and the data are uncorrected. For thin-layer chromatographic investigations, Merck 5554 silica gel 60F254 foils were used. Eluents: benzenermethanol =
8:2; kloroform:methanol = 9:1, og kloroform:aceton:ethyl-amin = 5:4:1 (v/v). Flekkene ble påvist i UV-lys og med 8:2; chloroform:methanol = 9:1, and chloroform:acetone:ethylamine = 5:4:1 (v/v). The spots were detected in UV light and with
et Dragendorff-reagens. PMR-spektre ble foretatt på en apparatur av type Bruker W200SY ved 200 MHz. De kjemiske skiftninger er indikert i S (ppm). Massespektrene ble foretatt på en apparatur av typen VG-703 5(GC-MS-DS) med elek-tronstøt-ionlseringsmetoden. a Dragendorff reagent. PMR spectra were taken on a Bruker W200SY apparatus at 200 MHz. The chemical shifts are indicated in S (ppm). The mass spectra were performed on an apparatus of the type VG-703 5 (GC-MS-DS) with the electron impact ionization method.
Eksempel 1 Example 1
N- demethyl- dihydrocodeinon N-demethyl-dihydrocodeinone
3 g (10 mmol) dihydrocodeinon ble oppløst i 60 ml 1,2-diklorethan, 1 g (10 mmol) natriumcarbonat ble tilsatt, og under omrøring ved en temperatur på 0°C ble 19,8 g (12 ml, 100 mmol) difosgen dråpevis tilsatt. Blandingen ble omrørt ved 0°C i 30 minutter, fikk deretter oppvarmes til romtemperatur og ble kokt under omrøring i 10 timer. Blandingen ble vasket grundig med nitrogen, det uorganiske salt ble filtrert fra. Løsningen inneholdende 1,2 diklorethan ble vasket med 3 x 20 ml 5% saltsyre (iskald), hvoretter den organiske fase ble fordampet i vakuum. 100 ml vann ble tilsatt til residuet som ble oppvarmet på et vannbad i 5 timer. Løsningen ble avkjølt til under 10°C og gjort alkalisk (pH-verdi = 9-10) med konsentrert ammoniumhydroxyd. Etter ekstraksjon med 3 x 50 ml kloroform ble den organiske fase vasket med saltvann og tørket over magnesiumsulfat. Utbytte: 2,33 g (82%), smp.: 150-151°C (ethylacetat) 3 g (10 mmol) of dihydrocodeinone was dissolved in 60 ml of 1,2-dichloroethane, 1 g (10 mmol) of sodium carbonate was added, and with stirring at a temperature of 0°C, 19.8 g (12 ml, 100 mmol) diphosgene added drop by drop. The mixture was stirred at 0°C for 30 minutes, then allowed to warm to room temperature and boiled with stirring for 10 hours. The mixture was washed thoroughly with nitrogen, the inorganic salt was filtered off. The solution containing 1,2 dichloroethane was washed with 3 x 20 ml of 5% hydrochloric acid (ice-cold), after which the organic phase was evaporated in vacuo. 100 ml of water was added to the residue which was heated on a water bath for 5 hours. The solution was cooled to below 10°C and made alkaline (pH value = 9-10) with concentrated ammonium hydroxide. After extraction with 3 x 50 ml chloroform, the organic phase was washed with salt water and dried over magnesium sulfate. Yield: 2.33 g (82%), mp: 150-151°C (ethyl acetate)
PMR (CDC13): 6,66 dd (H-1,2; 2H); 4,7 s (H-5P; 1H); 3,9 s PMR (CDCl 3 ): 6.66 dd (H-1.2; 2H); 4.7 s (H-5P; 1H); 3.9 p
(0CH3? 3H). (OHCH3?3H).
MS: m/e 285 (M<+>; 23%) MS: m/e 285 (M<+>; 23%)
0,4 g (13%) dihydrocodeinon kan gjenvinnes fra den 5%-ige saltsyreløsning ved at den gjøres alkalisk (konsentrert ammoniumhydroxyd) og ekstraheres (kloroform). 0.4 g (13%) of dihydrocodeinone can be recovered from the 5% hydrochloric acid solution by making it alkaline (concentrated ammonium hydroxide) and extracting (chloroform).
Eksempel 2 Example 2
N- d erne thy1- d ihydromorf inon N- d erne thy1- d ihydromorph inon
3,3 g (10 mmol) 3-0-acetyl-dihydromor.finon ble oppløst i 60 ml 1,2-diklorethan, lg (10 mmol) natriumcarbonat ble tilsatt, og under omrøring ved 0°C ble 19,8 g (12 ml, 3.3 g (10 mmol) of 3-O-acetyl-dihydromorphinone was dissolved in 60 ml of 1,2-dichloroethane, 1 g (10 mmol) of sodium carbonate was added, and with stirring at 0°C, 19.8 g ( 12 ml,
100 mmol) difosgen dråpevis tilsatt. Blandingen ble omrørt ved 0°C i 30 minutter, fikk deretter oppvarmes til romtemperatur og ble kokt under omrøring i 15 timer. Blandingen ble vasket med nitrogen, det uorganiske salt ble filtrert fra. Dette ble vasket med 3 x 20 ml 5% saltsyre, hvorpå den organiske fase ble fordampet i vakuum. 100 ml vann ble tilsatt til residuet som ble kokt i 8 timer. Blandingen 100 mmol) diphosgene added dropwise. The mixture was stirred at 0°C for 30 minutes, then allowed to warm to room temperature and boiled with stirring for 15 hours. The mixture was washed with nitrogen, the inorganic salt was filtered off. This was washed with 3 x 20 ml of 5% hydrochloric acid, after which the organic phase was evaporated in vacuo. 100 ml of water was added to the residue which was boiled for 8 hours. The mixture
ble avkjølt til under 10°C, og klorhydratet av produktet ble utskilt i krystallinsk form. Dette ble filtrert og vasket med kaldt vann. Utbytte: 2,15 g (70%) av klorhydrat. was cooled to below 10°C, and the hydrochloride of the product was separated in crystalline form. This was filtered and washed with cold water. Yield: 2.15 g (70%) of chlorohydrate.
Smeltepunktet av basen gjenvunnet fra dette: 300-303°C. Utgangsforbindelsen ble gjenvunnet fra 5% saltsyreløsningen som beskrevet i eksempel 1. Melting point of the base recovered from this: 300-303°C. The starting compound was recovered from the 5% hydrochloric acid solution as described in Example 1.
Eksempel 3 Example 3
N- demethylcodein N-demethylcodeine
3,41 g (10 mmol) 6-0-acetylcodein ble oppløst i 80 ml 1,2-diklorethan, 1 g (10 mmol) natriumcarbonat ble tilsatt, og under omrøring ved 0°C ble 19,8 g (12 ml, 100 mmol) difosgen dråpevis tilsatt. Blandingen ble omrørt ved 0°C i 30 minutter og fikk deretter oppvarmes til romtemperatur og ble omrørt og kokt i 20 timer. Blandingen ble vasket med nitrogen, og det uorganiske salt ble filtrert fra. Residuet ble vasket med 3 x 20 ml 5% saltsyre og ble deretter fordampet. Residuet ble kokt med 5% saltsyre i 5 timer. Løs-ningen ble deretter avkjølt til under 10°C, produktet utskiltes i krystallinsk form og ble filtrert fra og vasket med isvann. Det krystallinske klorhydrat ble oppløst i vann, gjort alkalisk med konsentrert ammoniumhydroxyd, ekstrahert med kloroform, hvorpå kloroformfasen ble tørket og fordampet. Den således erholdte base ble krystallisert fra aceton eller ethylacetat. 3.41 g (10 mmol) of 6-O-acetylcodeine was dissolved in 80 ml of 1,2-dichloroethane, 1 g (10 mmol) of sodium carbonate was added, and while stirring at 0°C, 19.8 g (12 ml, 100 mmol) diphosgene added dropwise. The mixture was stirred at 0°C for 30 minutes and then allowed to warm to room temperature and was stirred and boiled for 20 hours. The mixture was flushed with nitrogen and the inorganic salt was filtered off. The residue was washed with 3 x 20 ml of 5% hydrochloric acid and then evaporated. The residue was boiled with 5% hydrochloric acid for 5 hours. The solution was then cooled to below 10°C, the product separated in crystalline form and was filtered off and washed with ice water. The crystalline chlorohydrate was dissolved in water, made alkaline with concentrated ammonium hydroxide, extracted with chloroform, whereupon the chloroform phase was dried and evaporated. The base thus obtained was crystallized from acetone or ethyl acetate.
Utbytte: 2,3 g (80%), smp. 185°C. Yield: 2.3 g (80%), m.p. 185°C.
PMR (CDC13): 6,65 dd (H-1,2; 2H); 5,7 m (H-8; 1H); PMR (CDCl 3 ): 6.65 dd (H-1.2; 2H); 5.7 m (H-8; 1H);
5,3 m (H-7; 1H); 4,9 d (H-53; 1H); 4,2 m 5.3 m (H-7; 1H); 4.9d (H-53; 1H); 4.2 m
(H-63; 1H) ; 3,8 s (OMe; 3H). (H-63; 1H); 3.8 s (OMe; 3H).
MS: m/e 285 (M<+>; 100%), 215 (50%). MS: m/e 285 (M<+>; 100%), 215 (50%).
Eksempel 4 Example 4
N- demethyl- dihydrocodein N-demethyl-dihydrocodeine
3,43 g (10 mmol) 6-0-acetyl-dihydrocodein ble N-demethylert som beskrevet i eksempel 3. Etter syrehydrolyse under avkjøling utskiltes ikke hydrokloridsaltet fra løs-ningen, hvorfor denne ble direkte gjort alkalisk med konsen- 3.43 g (10 mmol) of 6-0-acetyl-dihydrocodeine was N-demethylated as described in example 3. After acid hydrolysis while cooling, the hydrochloride salt was not separated from the solution, which is why it was directly made alkaline with conc.
trert ammoniumhydroxyd, hvorpå produktet ble erholdt ved klorof ormeks tråkas jon £og ble "Krystallisert fra ethanol. Utbytte: 1,9 g (66%), smp. 194°C. triturated ammonium hydroxide, whereupon the product was obtained by chloroform extn. and crystallized from ethanol. Yield: 1.9 g (66%), m.p. 194°C.
PMR (CDC13): 6,7 dd (H-1,2; 2H) ; 4,6 d (H-53; 1H) ; 4,1 m PMR (CDCl 3 ): 6.7 dd (H-1,2; 2H); 4.6d (H-53; 1H); 4.1 m
(H-63; 1H) ; 3,8 s (OMe; 3H) (H-63; 1H); 3.8 s (OMe; 3H)
MS: m/e 287 (M<+>; 100%). MS: m/e 287 (M<+>; 100%).
Eksempel 5 Example 5
N- demethylmorf in N-demethylmorph in
3,7 g (10 mmol) 3,6-di-0-acetylmorfin ble oppløst i 100 ml 1,2-diklorethan og ble deretter N-demethylert som beskrevet i eksempel 3. Etter avkjøling av saltsyreløs-ningen ble pH-verdien justert til 9 med konsentrert ammoniumhydroxyd. Produktet utskiltes i krystallinsk form og ble filtrert og vasket med kaldt vann. Utbytte: 2,1 g (77%); idet det først ble erholdt 1,8 g og deretter 0,3 g fra den alkaliske løsning under anvendelse av kloroform-isopropanol (3:1, v/v) ved ekstraksjon. Smp. 274-277°C. 3.7 g (10 mmol) of 3,6-di-0-acetylmorphine was dissolved in 100 ml of 1,2-dichloroethane and was then N-demethylated as described in example 3. After cooling the hydrochloric acid solution, the pH value was adjusted to 9 with concentrated ammonium hydroxide. The product separated in crystalline form and was filtered and washed with cold water. Yield: 2.1 g (77%); obtaining first 1.8 g and then 0.3 g from the alkaline solution using chloroform-isopropanol (3:1, v/v) by extraction. Temp. 274-277°C.
PMR (DMSO-dg): 6,4 dd (H-1,2; 2H); 5,6 m (H-8; 1H); 5,2 m (H-7; 1H); 4,7 dd (H-53? 1H); 4,1 m PMR (DMSO-dg): 6.4 dd (H-1,2; 2H); 5.6 m (H-8; 1H); 5.2 m (H-7; 1H); 4.7 dd (H-53? 1H); 4.1 m
(H-63; 1H) (H-63; 1H)
MS: m/e 271 (M<+>; 100%); 201 (51%). MS: m/e 271 (M<+>; 100%); 201 (51%).
Eksempel 6 Example 6
N- demethyl- dihydromorfin N-demethyl-dihydromorphine
3,71 g (10 mmol) 3,6-di-0-acetyl-dihydromorfin ble oppløst i 100 ml 1,2-diklorethan og ble N-demethylert som beskrevet i eksempel 5. 3.71 g (10 mmol) of 3,6-di-O-acetyl-dihydromorphine was dissolved in 100 ml of 1,2-dichloroethane and was N-demethylated as described in example 5.
Utbytte: 1,65 g (60%), smp. 262-266°C. Yield: 1.65 g (60%), m.p. 262-266°C.
PMR (DMS0-d6); 6,5 dd (H-1,2; 2H); 4,2 d (H-53; 1H); PMR (DMS0-d6); 6.5 dd (H-1,2; 2H); 4.2d (H-53; 1H);
3,8 m (H-63; 1H) 3.8 m (H-63; 1H)
MS: m/e 273 (M<+>; 100%); 228 (22%); 150 (45%). MS: m/e 273 (M<+>; 100%); 228 (22%); 150 (45%).
Eksempel 7 Example 7
N- demethylmorfln- 3- ethyletner N-demethylmorphln-3-ethylethene
3,55 g (10 mmol) 6-0-acetyl-ethylmorfin ble N-demethylert som beskrevet i eksempel 3. Under avkjøling ut- 3.55 g (10 mmol) of 6-0-acetyl-ethylmorphine was N-demethylated as described in example 3. During cooling,
skiltes klorhydratet av produktet som ble filtrert og vasket med kaldt vann. Fra dette ble basen gjenvunnet og krystallisert fra ethanol. the chloral hydrate was separated from the product, which was filtered and washed with cold water. From this the base was recovered and crystallized from ethanol.
Utbytte: 2,5 g (84%), smp. 156-157°C. Yield: 2.5 g (84%), m.p. 156-157°C.
Eksempel 8 Example 8
N- demethyl- dihydromorfln- 3- ethylether N-demethyl-dihydromorphln-3-ethyl ether
3,57 g (10 mmol) 6-0-acetyl-dihydroethylmorfin ble N-demethylert som beskrevet i eksempel 4. Produktet ble erholdt ved at saltsyreløsningen ble gjort alkalisk etter-fulgt av ekstraksjon, hvorpå produktet ble krystallisert fra ethylacetat. 3.57 g (10 mmol) of 6-0-acetyl-dihydroethylmorphine was N-demethylated as described in example 4. The product was obtained by making the hydrochloric acid solution alkaline followed by extraction, after which the product was crystallized from ethyl acetate.
Utbytte: 2,32 g (77%), smp. 128-131°C. Yield: 2.32 g (77%), m.p. 128-131°C.
PMR (CDC13): 6,6 dd (H-1,2; 2H); 4,5 d (H-53; 1H); 4,1 m (0-CH2-CH3; 2H); 3,95 m (H-63; 1H); 1,4 t PMR (CDCl 3 ): 6.6 dd (H-1.2; 2H); 4.5 d (H-53; 1H); 4.1 m (O-CH 2 -CH 3 ; 2H); 3.95 m (H-63; 1H); 1.4 h
(0-CH2-CH3; 3H) (0-CH2-CH3; 3H)
MS: m/e 301 (M<+>; 100%) MS: m/e 301 (M<+>; 100%)
Eksempel 9 Example 9
N- demethyl- desoxycodein- E N- demethyl- desoxycodein- E
1,42 g (5 mmol) desoxycodein-E ble oppløst i 50 ml 1,2-diklorethan. 0,5 g (5 mmol) natriumcarbonat ble tilsatt, og til den erholdte suspensjon ble 6,0 ml (50 mmol) difosgen dråpevis tilsatt under omrøring og under avkjøling. Etter 30 minutters omrøring ble avkjølingen stanset, hvorpå blandingen ble kokt i 15 timer under omrøring. Etter avkjøling ble blandingen vasket med nitrogen, og det uorganiske salt ble deretter filtrert, og den organiske fase ble vasket med 2 x 20 ml kald 5% saltsyre og saltvann. Diklorethanet ble fordampet i vakuum, til residuet ble tilsatt 60 ml vann, og blandingen ble oppvarmet på et vannbad i 8 timer. Etter avkjøling ble blandingen gjort alkalisk (pH 10; konsentrert NH^OH) og ble ekstrahert med 3 x 30 ml kloroform. Etter tørking av kloroformen (magnesiumsulfat) ble det erholdt 0,6 g (60%) N-demethyl-desoxycodein-E som var homogent i henhold til tynnskiktskromatografi. Basen krystalliserte ikke ut, men når en alkoholisk løsning derav surgjøres med 1.42 g (5 mmol) of desoxycodein-E was dissolved in 50 ml of 1,2-dichloroethane. 0.5 g (5 mmol) sodium carbonate was added, and to the resulting suspension 6.0 ml (50 mmol) diphosgene was added dropwise while stirring and while cooling. After 30 minutes of stirring, the cooling was stopped, after which the mixture was boiled for 15 hours with stirring. After cooling, the mixture was flushed with nitrogen, and the inorganic salt was then filtered, and the organic phase was washed with 2 x 20 mL of cold 5% hydrochloric acid and brine. The dichloroethane was evaporated in vacuo to the residue, 60 ml of water was added, and the mixture was heated on a water bath for 8 hours. After cooling, the mixture was made alkaline (pH 10; conc. NH 3 OH) and was extracted with 3 x 30 ml chloroform. After drying the chloroform (magnesium sulfate), 0.6 g (60%) of N-demethyl-desoxycodein-E was obtained which was homogeneous according to thin layer chromatography. The base did not crystallize out, but when an alcoholic solution of it was acidified with
48% hydrogenbromid, kan krystallinsk hydrobromid erholdes. Smeltepunkt: 307-310°C (smeltepunkt i henhold til litteraturen: 311-312°C, R.L. Clark et al.: J. Am. Chem. Soc. 75, 4963 (1953)). 48% hydrogen bromide, crystalline hydrobromide can be obtained. Melting point: 307-310°C (literature melting point: 311-312°C, R.L. Clark et al.: J. Am. Chem. Soc. 75, 4963 (1953)).
Eksempel 10 Example 10
N- demethyl- dihydrodesoxycodein- E N- demethyl- dihydrodesoxycodein- E
1,4 mg (5 mmol) dihydrodesoxycodein-E ble anvendt som utgangsforbindelse og ble bearbeidet som beskrevet i eksempel 9. Etter ekstraksjon med kloroform ble det erholdt 0,4 5 g (33%) krystallinsk N-demethyl-dihydrodesoxycodein-E. Etter at produktet var krystallisert fra ethylacetat, var smeltepunktet 91-92°C (smeltepunkt i henhold til litteraturen: 92-94°C? R.L. Clark et al.: J. Am. Chem. Soc. 25, 4963 (1953)). 1.4 mg (5 mmol) of dihydrodesoxycodein-E was used as starting compound and was processed as described in example 9. After extraction with chloroform, 0.45 g (33%) of crystalline N-demethyl-dihydrodesoxycodein-E was obtained. After the product was crystallized from ethyl acetate, the melting point was 91-92°C (literature melting point: 92-94°C? R.L. Clark et al.: J. Am. Chem. Soc. 25, 4963 (1953)).
Claims (3)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU842774A HU197750B (en) | 1984-07-17 | 1984-07-17 | Process for n-demethylation of morphine alkaloids |
Publications (3)
Publication Number | Publication Date |
---|---|
NO852838L NO852838L (en) | 1986-01-20 |
NO161915B true NO161915B (en) | 1989-07-03 |
NO161915C NO161915C (en) | 1989-10-11 |
Family
ID=10961043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO852838A NO161915C (en) | 1984-07-17 | 1985-07-16 | PROCEDURE FOR N-DEMETHYLING OF MORPHINAN ALKALOIDS. |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0168686B1 (en) |
JP (1) | JPS6193184A (en) |
AT (1) | ATE41933T1 (en) |
BG (1) | BG44029A3 (en) |
CS (1) | CS251792B2 (en) |
DD (1) | DD235639A5 (en) |
DE (1) | DE3569244D1 (en) |
DK (1) | DK322385A (en) |
ES (1) | ES8603716A1 (en) |
FI (1) | FI81583C (en) |
HU (1) | HU197750B (en) |
IL (2) | IL75509A0 (en) |
IN (1) | IN166255B (en) |
NO (1) | NO161915C (en) |
PL (1) | PL254552A1 (en) |
RO (1) | RO91516B (en) |
SU (1) | SU1398776A3 (en) |
YU (1) | YU45264B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5688974B2 (en) * | 2007-12-17 | 2015-03-25 | マリンクロッド エルエルシー | Processes and compounds for the production of (+)-opiates |
JP5579076B2 (en) * | 2007-12-17 | 2014-08-27 | マリンクロッド エルエルシー | Sinomenin derivatives and processes for their synthesis |
GB2482826B (en) * | 2009-05-12 | 2015-03-11 | Univ Texas | Synthesis of morphine and related derivatives |
CA2768199C (en) * | 2010-07-16 | 2018-08-28 | Mallinckrodt Llc | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
RU2014112493A (en) | 2011-09-08 | 2015-10-20 | МАЛЛИНКРОДТ Эл-Эл-Си | PRODUCTION OF ALKALOIDS WITHOUT ISOLATION OF INTERMEDIATE PRODUCTS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1584088A (en) * | 1967-08-04 | 1969-12-12 | ||
DE2254298A1 (en) * | 1972-11-06 | 1974-05-16 | Boehringer Sohn Ingelheim | Heteroarylmethyl-normorphines prepn - by alkylation of normorphine etc., antidotes for opiate poisoning |
DE2727805A1 (en) * | 1977-06-21 | 1979-01-04 | Goedecke Ag | METHOD FOR PRODUCING OXYNORMORPHONE |
-
1984
- 1984-07-17 HU HU842774A patent/HU197750B/en not_active IP Right Cessation
-
1985
- 1985-06-13 IL IL75509A patent/IL75509A0/en not_active IP Right Cessation
- 1985-06-14 IN IN476/DEL/85A patent/IN166255B/en unknown
- 1985-06-20 ES ES544385A patent/ES8603716A1/en not_active Expired
- 1985-06-26 DE DE8585107895T patent/DE3569244D1/en not_active Expired
- 1985-06-26 AT AT85107895T patent/ATE41933T1/en not_active IP Right Cessation
- 1985-06-26 EP EP85107895A patent/EP0168686B1/en not_active Expired
- 1985-07-12 DD DD85278546A patent/DD235639A5/en not_active IP Right Cessation
- 1985-07-15 RO RO119568A patent/RO91516B/en unknown
- 1985-07-15 BG BG8571084A patent/BG44029A3/en unknown
- 1985-07-15 PL PL25455285A patent/PL254552A1/en unknown
- 1985-07-15 FI FI852779A patent/FI81583C/en not_active IP Right Cessation
- 1985-07-15 DK DK322385A patent/DK322385A/en not_active Application Discontinuation
- 1985-07-16 JP JP60156846A patent/JPS6193184A/en active Pending
- 1985-07-16 CS CS855280A patent/CS251792B2/en unknown
- 1985-07-16 SU SU853923700A patent/SU1398776A3/en active
- 1985-07-16 NO NO852838A patent/NO161915C/en unknown
- 1985-07-17 YU YU1174/85A patent/YU45264B/en unknown
-
1986
- 1986-04-15 IL IL78503A patent/IL78503A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
FI852779A0 (en) | 1985-07-15 |
YU117485A (en) | 1988-04-30 |
DE3569244D1 (en) | 1989-05-11 |
EP0168686A1 (en) | 1986-01-22 |
DD235639A5 (en) | 1986-05-14 |
CS528085A2 (en) | 1986-12-18 |
PL254552A1 (en) | 1986-07-15 |
FI81583C (en) | 1990-11-12 |
YU45264B (en) | 1992-05-28 |
DK322385D0 (en) | 1985-07-15 |
IL75509A0 (en) | 1985-10-31 |
NO161915C (en) | 1989-10-11 |
IL78503A (en) | 1990-01-18 |
IN166255B (en) | 1990-03-31 |
EP0168686B1 (en) | 1989-04-05 |
NO852838L (en) | 1986-01-20 |
FI852779L (en) | 1986-01-18 |
FI81583B (en) | 1990-07-31 |
JPS6193184A (en) | 1986-05-12 |
RO91516A (en) | 1987-06-30 |
BG44029A3 (en) | 1988-09-15 |
DK322385A (en) | 1986-01-18 |
HUT38645A (en) | 1986-06-30 |
ATE41933T1 (en) | 1989-04-15 |
ES8603716A1 (en) | 1986-01-16 |
RO91516B (en) | 1987-07-01 |
SU1398776A3 (en) | 1988-06-15 |
ES544385A0 (en) | 1986-01-16 |
CS251792B2 (en) | 1987-08-13 |
HU197750B (en) | 1989-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4613668A (en) | Short total synthesis or morphinan compounds which uses cyclization of a cycloalkylcarbonyl compound selected from cyclopropylcarbonyl and cyclobutylcarbonyl | |
US6365742B1 (en) | Preparation of opiates, intermediates and uses of salts | |
US4472253A (en) | Process for the preparation of an N-substituted 3-O-alkyl-14-hydroxynormorphinone derivative | |
US4161597A (en) | N-alkyl-14-hydroxymorphinans and derivatives | |
WO2009003270A1 (en) | Methods for one-pot n-demethylation/n-acylation of morphine and tropane alkaloids | |
AU2018268173B2 (en) | Preparation of buprenorphine | |
US20180319750A1 (en) | Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamdes | |
NO161915B (en) | PROCEDURE FOR N-DEMETHYLING OF MORPHINAN ALKALOIDS. | |
EP0496830A4 (en) | Total synthesis of northebaine, normorphine, noroxymorphone enantiomers and derivatives via n-nor intermediates | |
EP2480555A2 (en) | Methods for producing hydrocodone, hydromorphone or a derivative thereof | |
DK160048B (en) | PROCEDURE FOR DEALKYLING OF 14-HYDROXY MORPHINANALKALOIDS | |
AU2007267439B2 (en) | Process for the demethylation of oxycodone and related compounds | |
JPWO2006129626A1 (en) | Process for producing [1,2,4] triazolo [1,5-c] pyrimidine derivatives | |
EP1846371B1 (en) | Process for producing [1,4']bipiperidinyl-1'-carbonyl chloride or hydrochloride thereof | |
NO131149B (en) | ||
Kim | N-Demethylation of Apomorphine using Methyl Chloroformate | |
CA2299200C (en) | Process for the preparation of endo-nortropine using 8-benzyl-nortropan-3-one perchlorate as the intermediate, as well as the latter salt | |
CA2269910A1 (en) | New process for the preparation of morphinans | |
Horikiri et al. | Syntheses of 10-Oxo, 10α-Hydroxy, and 10β-Hydroxy Derivatives of a Potent κ-Opioid Receptor Agonist, TRK-820 | |
JPH04217980A (en) | Preparation of octahydropyrazolo- (3,4-g)quinoline | |
GB2444052A (en) | Processes of preparing morphinan derivatives such as naltrexone and naloxone comprising O- and N-demethylation and reductive alkylation steps | |
JP2023526351A (en) | Method for producing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine carboxylate | |
TAKAI et al. | Synthesis of 1′-Substituted 2-Amino-spiro [4H-3, 1-benzoxazine-4, 4′-piperidine] Derivatives | |
NO134985B (en) | ||
PL71358B1 (en) |